Evidence map›Paper›PMID 35378331›Full record

ArticleCellular and molecular gastroenterology and hepatology2022

The Host-Microbiome Response to Hyperbaric Oxygen Therapy in Ulcerative Colitis Patients.

Carlos G Gonzalez, Robert H Mills, Melissa C Kordahi, Marvic Carrillo-Terrazas, Henry Secaira-Morocho, Christella E Widjaja, Matthew S Tsai, Yash Mittal, Brian A Yee, Fernando Vargas and 26 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Effects of Hyperbaric Oxygen Therapy forJournal of the anus, rectum and colon · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 8 institutions in 2 countries.

Carlos G GonzalezDepartment of Pharmacology, University of California, San Diego, California; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California; Department of Pediatrics, University of California, San Diego, California.
Robert H MillsDepartment of Pharmacology, University of California, San Diego, California; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California; Department of Pediatrics, University of California, San Diego, California.
Melissa C KordahiINSERM U1016, team "Mucosal microbiota in chronic inflammatory diseases", CNRS UMR 8104, Université de Paris, Paris, France.
Marvic Carrillo-TerrazasDepartment of Pharmacology, University of California, San Diego, California; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California.
Henry Secaira-MorochoSchool of Life Sciences, Arizona State University, Tempe, Arizona; Biodesign Center for Fundamental and Applied Microbiomics, Arizona State University, Tempe, Arizona.
Christella E WidjajaDivision of Gastroenterology, University of California San Diego, San Diego, California.
Matthew S TsaiDivision of Gastroenterology, University of California San Diego, San Diego, California.
Yash MittalDivision of Gastroenterology, University of California San Diego, San Diego, California.
Brian A YeeDepartment of Cellular and Molecular Medicine, University of California San Diego, San Diego, California; Institute for Genomic Medicine, University of California San Diego, San Diego, California.
Fernando VargasSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California.
Kelly WeldonSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California; Department of Computer Science and Engineering, University of California San Diego, San Diego, California.
Julia M GauglitzDepartment of Pediatrics, University of California, San Diego, California.
Clara DelaroqueINSERM U1016, team "Mucosal microbiota in chronic inflammatory diseases", CNRS UMR 8104, Université de Paris, Paris, France.
Consuelo SaucedaDepartment of Pharmacology, University of California, San Diego, California.
Leigh-Ana RossittoDepartment of Pharmacology, University of California, San Diego, California.
Gail AckermannDepartment of Pediatrics, University of California, San Diego, California.
Gregory HumphreyDepartment of Pediatrics, University of California, San Diego, California.
Austin D SwaffordDepartment of Computer Science and Engineering, University of California San Diego, San Diego, California.
Corey A SiegelSection of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
Jay C BuckeyCenter for Hyperbaric Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
Laura E RaffalsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Charlotte SadlerDivision of Hyperbaric Medicine, Department of Emergency Medicine, University of California San Diego, San Diego, California.
Peter LindholmDivision of Hyperbaric Medicine, Department of Emergency Medicine, University of California San Diego, San Diego, California.
Kathleen M FischCenter for Computational Biology and Bioinformatics, University of California San Diego, San Diego, California.
Mark ValaseckDepartment of Pathology, University of California San Diego, San Diego, California.
Arief SuriawinataSection of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
Gene W YeoDepartment of Cellular and Molecular Medicine, University of California San Diego, San Diego, California; Institute for Genomic Medicine, University of California San Diego, San Diego, California.
Pradipta GhoshDivision of Gastroenterology, University of California San Diego, San Diego, California; Department of Cellular and Molecular Medicine, University of California San Diego, San Diego, California.
John T ChangDivision of Gastroenterology, University of California San Diego, San Diego, California.
Hiutung ChuDepartment of Pathology, University of California San Diego, San Diego, California; Center for Microbiome Innovation, University of California San Diego, San Diego, California; Chiba University-UC San Diego Center for Mucosal Immunology, Allergy and Vaccines (cMAV), University of California, San Diego, La Jolla, California.
Pieter DorresteinSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California; Department of Pediatrics, University of California, San Diego, California; Center for Microbiome Innovation, University of California San Diego, San Diego, California.
Qiyun ZhuSchool of Life Sciences, Arizona State University, Tempe, Arizona; Biodesign Center for Fundamental and Applied Microbiomics, Arizona State University, Tempe, Arizona.
Benoit ChassaingINSERM U1016, team "Mucosal microbiota in chronic inflammatory diseases", CNRS UMR 8104, Université de Paris, Paris, France.
Rob KnightDepartment of Computer Science and Engineering, University of California San Diego, San Diego, California; Department of Pediatrics, University of California, San Diego, California; Center for Microbiome Innovation, University of California San Diego, San Diego, California.
David J GonzalezDepartment of Pharmacology, University of California, San Diego, California; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California; Center for Microbiome Innovation, University of California San Diego, San Diego, California.
Parambir S DulaiDivision of Gastroenterology, University of California San Diego, San Diego, California; Division of Gastroenterology, Northwestern University, Chicago, Illinois. Electronic address: parambir.dulai@northwestern.edu.
University of California San Diego · USUniversity of San Diego · USCentre National de la Recherche Scientifique · FRDartmouth–Hitchcock Medical Center · USArizona State University · USUniversity of California System · USMayo Clinic · USNorthwestern University · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
UCSD/SDSU IRACDAK12GM068524 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2003 to 2025
$24.4M
GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN, Bernd G. Schnabl · 2019 to 2026
$10.8M
Single-Cell Transcriptomic and Epigenetics CoreP01AI132122 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZUNIGA, ELINA I · 2018 to 2022
$9.8M
Training Grant in GastroenterologyT32DK007202 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 1985 to 2022
$7.7M
Macrophage Polarization in Response to Infections and InflammationR01AI155696 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, SAHOO, DEBASHIS · 2020 to 2024
$4.9M
UC San Diego Clinical and Translational Research InstituteTL1TR001443 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2019
$3.4M
Modulation of Macrophage Polarization by Heterotrimeric G proteins: Implications of Gastrointestinal InflammationR01AI141630 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Pradipta Ghosh · 2019 to 2026
$3.2M
Using single-cell RNA-seq to interrogate host immunity to pathogensR01AI123202 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHANG, JOHN T, YEO, EUGENE WEI-MING · 2016 to 2020
$3.1M
Role of proteasome activity in adaptive immunityR01AI129973 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHANG, JOHN T · 2018 to 2022
$2.2M
Precision therapeutics of inflammatory bowel disease guided by Boolean logicUG3TR003355 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAS, SOUMITA, GHOSH, PRADIPTA · 2020 to 2022
$937k
NCATS NIH HHS TL1 TR001443NCATS NIH HHS UG3 TR003355NCATS NIH HHS UL1 TR001442NIAID NIH HHS P01 AI132122NIAID NIH HHS R01 AI123202NIAID NIH HHS R01 AI129973NIAID NIH HHS R01 AI141630NIAID NIH HHS R01 AI155696NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R21 DK119724NIDDK NIH HHS T32 DK007202NIDDK NIH HHS U34 DK126626NIGMS NIH HHS K12 GM068524NIGMS NIH HHS T32 GM007752
6 · The paper itself

Abstract

BACKGROUND &

aimsHyperbaric oxygen therapy (HBOT) is a promising treatment for moderate-to-severe ulcerative colitis. However, our current understanding of the host and microbial response to HBOT remains unclear. This study examined the molecular mechanisms underpinning HBOT using a multi-omic strategy.

methodsPre- and post-intervention mucosal biopsies, tissue, and fecal samples were collected from HBOT phase 2 clinical trials. Biopsies and fecal samples were subjected to shotgun metaproteomics, metabolomics, 16s rRNA sequencing, and metagenomics. Tissue was subjected to bulk RNA sequencing and digital spatial profiling (DSP) for single-cell RNA and protein analysis, and immunohistochemistry was performed. Fecal samples were also used for colonization experiments in IL10

resultsProteomics identified negative associations between HBOT response and neutrophil azurophilic granule abundance. DSP identified an HBOT-specific reduction of neutrophil STAT3, which was confirmed by immunohistochemistry. HBOT decreased microbial diversity with a proportional increase in Firmicutes and a secondary bile acid lithocholic acid. A major source of the reduction in diversity was the loss of mucus-adherent taxa, resulting in increased MUC2 levels post-HBOT. Targeted database searching revealed strain-level associations between Akkermansia muciniphila and HBOT response status. Colonization of IL10

conclusionsHBOT reduces host neutrophil STAT3 and azurophilic granule activity in UC patients and changes in microbial composition and metabolism in ways that improve colitis activity. Intestinal microbiota, especially strain level variations in A muciniphila, may contribute to HBOT non-response.

Indexed as

Colitis, UlcerativeHyperbaric OxygenationMicrobiotaAnimalsHumansInterleukin-10MiceRNA, Ribosomal, 16SInterleukin-10RNA, Ribosomal, 16S

Identifiers

PMID35378331
PMCPMC9117812
OpenAlexW4224308954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.